Aerpio Pharmaceuticals Stock Forecast, Price & News

-0.08 (-5.93 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $1.27
50-Day Range
MA: $1.56
52-Week Range
Now: $1.27
Volume646,582 shs
Average Volume2.18 million shs
Market Capitalization$60.09 million
P/E RatioN/A
Dividend YieldN/A
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.
Aerpio Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARPO
Phone513 985 1920
Year FoundedN/A



Sales & Book Value

Annual Sales$20.16 million
Book Value$0.90 per share


Net Income$-23,270,000.00


Market Cap$60.09 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Horizon (HZNP) Provides Preliminary 2020 Financial Results
January 12, 2021 |
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
December 31, 2020 |
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU
December 30, 2020 |
See More Headlines


Overall MarketRank

1.15 out of 5 stars

Medical Sector

953rd out of 2,016 stocks

Pharmaceutical Preparations Industry

454th out of 771 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.08 (-5.93 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aerpio Pharmaceuticals (NASDAQ:ARPO) Frequently Asked Questions

Is Aerpio Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aerpio Pharmaceuticals stock.
View analyst ratings for Aerpio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Aerpio Pharmaceuticals?

Wall Street analysts have given Aerpio Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aerpio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals saw a drop in short interest in March. As of March 31st, there was short interest totaling 988,400 shares, a drop of 18.3% from the March 15th total of 1,210,000 shares. Based on an average trading volume of 2,030,000 shares, the short-interest ratio is currently 0.5 days. Approximately 2.5% of the company's stock are sold short.
View Aerpio Pharmaceuticals' Short Interest

When is Aerpio Pharmaceuticals' next earnings date?

Aerpio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Aerpio Pharmaceuticals

How were Aerpio Pharmaceuticals' earnings last quarter?

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) announced its quarterly earnings results on Wednesday, March, 10th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03.
View Aerpio Pharmaceuticals' earnings history

How has Aerpio Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Aerpio Pharmaceuticals' stock was trading at $0.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARPO stock has increased by 135.2% and is now trading at $1.27.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARPO?

2 brokerages have issued twelve-month price objectives for Aerpio Pharmaceuticals' shares. Their forecasts range from $1.50 to $4.00. On average, they anticipate Aerpio Pharmaceuticals' stock price to reach $2.75 in the next year. This suggests a possible upside of 116.5% from the stock's current price.
View analysts' price targets for Aerpio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the following people:
  • Dr. Joseph H. Gardner, Founder, Pres, Principal Exec. Officer & Director (Age 65, Pay $620.57k)
  • Ms. Regina Marek, Principal Financial Officer, Principal Accounting Officer & VP of Fin. (Age 52, Pay $316.72k)
  • Dr. Dhaval Desai, Chief Strategy Officer (Age 43)

Who are some of Aerpio Pharmaceuticals' key competitors?

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARPO."

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $1.27.

How much money does Aerpio Pharmaceuticals make?

Aerpio Pharmaceuticals has a market capitalization of $60.09 million and generates $20.16 million in revenue each year. The company earns $-23,270,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

How many employees does Aerpio Pharmaceuticals have?

Aerpio Pharmaceuticals employs 12 workers across the globe.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is

Where are Aerpio Pharmaceuticals' headquarters?

Aerpio Pharmaceuticals is headquartered at 9987 CARVER ROAD, CINCINNATI OH, 45242.

How can I contact Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513 985 1920 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.